Last reviewed · How we verify
ramucirumab (IMC-1121B)
Ramucirumab is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.
Ramucirumab is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis. Used for Metastatic gastric cancer, Non-small cell lung cancer, Advanced or metastatic breast cancer.
At a glance
| Generic name | ramucirumab (IMC-1121B) |
|---|---|
| Also known as | IMC-1121B, LY3009806, Ramucirumab |
| Sponsor | Eli Lilly and Company |
| Drug class | Angiogenesis inhibitor |
| Target | VEGFR2 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to VEGFR2, ramucirumab prevents the formation of new blood vessels, which is essential for tumor growth and metastasis. This mechanism is particularly effective in treating cancers that are highly vascularized.
Approved indications
- Metastatic gastric cancer
- Non-small cell lung cancer
- Advanced or metastatic breast cancer
Common side effects
- Fatigue
- Headache
- Nausea
Key clinical trials
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (PHASE2, PHASE3)
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (PHASE2)
- Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade (PHASE2)
- Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) (PHASE2, PHASE3)
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) (PHASE2)
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) (PHASE2)
- Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |